Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1951 2
1956 1
1958 1
1959 2
1961 4
1962 4
1963 7
1964 14
1965 9
1966 17
1967 14
1968 14
1969 27
1970 16
1971 12
1972 13
1973 19
1974 24
1975 23
1976 17
1977 23
1978 28
1979 21
1980 19
1981 35
1982 38
1983 34
1984 39
1985 34
1986 43
1987 51
1988 47
1989 57
1990 56
1991 63
1992 59
1993 56
1994 88
1995 62
1996 74
1997 70
1998 81
1999 89
2000 101
2001 106
2002 99
2003 127
2004 118
2005 119
2006 131
2007 113
2008 119
2009 125
2010 146
2011 155
2012 173
2013 163
2014 151
2015 159
2016 158
2017 194
2018 149
2019 194
2020 220
2021 276
2022 238
2023 244
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

4,759 results

Results by year

Filters applied: . Clear all
Page 1
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D. Sato Y, et al. Among authors: matsumoto h. Chest. 2022 Nov;162(5):1188-1198. doi: 10.1016/j.chest.2022.05.035. Epub 2022 Jun 1. Chest. 2022. PMID: 35661746
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: matsumoto h. Eur J Cancer. 2021 Dec;159:144-153. doi: 10.1016/j.ejca.2021.09.041. Epub 2021 Nov 5. Eur J Cancer. 2021. PMID: 34749119
Deep learning-enabled coronary CT angiography for plaque and stenosis quantification and cardiac risk prediction: an international multicentre study.
Lin A, Manral N, McElhinney P, Killekar A, Matsumoto H, Kwiecinski J, Pieszko K, Razipour A, Grodecki K, Park C, Otaki Y, Doris M, Kwan AC, Han D, Kuronuma K, Flores Tomasino G, Tzolos E, Shanbhag A, Goeller M, Marwan M, Gransar H, Tamarappoo BK, Cadet S, Achenbach S, Nicholls SJ, Wong DT, Berman DS, Dweck M, Newby DE, Williams MC, Slomka PJ, Dey D. Lin A, et al. Among authors: matsumoto h. Lancet Digit Health. 2022 Apr;4(4):e256-e265. doi: 10.1016/S2589-7500(22)00022-X. Lancet Digit Health. 2022. PMID: 35337643 Free PMC article.
[PATHOPHYSIOLOGY OF ASTHMA].
Matsumoto H. Matsumoto H. Arerugi. 2022;71(9):1065-1071. doi: 10.15036/arerugi.71.1065. Arerugi. 2022. PMID: 36372415 Japanese. No abstract available.
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility.
Fujimoto D, Morimoto T, Tamiya M, Hata A, Matsumoto H, Nakamura A, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Yokoi T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Hara S, Saito G, Miura S, Kanazu M, Yamamoto N, Akamatsu H. Fujimoto D, et al. Among authors: matsumoto h. JAMA Netw Open. 2023 Feb 1;6(2):e230698. doi: 10.1001/jamanetworkopen.2023.0698. JAMA Netw Open. 2023. PMID: 36826813 Free PMC article.
Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma.
Matsubara N, Yonese J, Kojima T, Azuma H, Matsumoto H, Powles T, Rosenberg JE, Petrylak DP, Matsangou M, Wu C, Campbell M, Yamashiro M. Matsubara N, et al. Among authors: matsumoto h. Cancer Med. 2023 Feb;12(3):2761-2771. doi: 10.1002/cam4.5165. Epub 2022 Sep 2. Cancer Med. 2023. PMID: 36052536 Free PMC article. Clinical Trial.
Response to the letter.
Okoshi K, Hida K, Kinoshita K, Morishima T, Nagai Y, Tomizawa Y, Yorozuya K, Nishida T, Matsumoto H, Yamato H. Okoshi K, et al. Among authors: matsumoto h. Surg Today. 2022 Sep;52(9):1393-1394. doi: 10.1007/s00595-022-02551-2. Epub 2022 Jul 13. Surg Today. 2022. PMID: 35829794 No abstract available.
Total Synthesis of Alcyonolide.
Fumiyama H, Takahashi A, Suzuki Y, Fujioka N, Matsumoto H, Hosokawa S. Fumiyama H, et al. Among authors: matsumoto h. J Org Chem. 2022 Nov 18;87(22):15492-15498. doi: 10.1021/acs.joc.2c02031. Epub 2022 Nov 3. J Org Chem. 2022. PMID: 36326030
4,759 results